DNL919

Denali Therapeutics Inc. · Phase 1 active Small molecule

At a glance

Generic name	DNL919
Sponsor	Denali Therapeutics Inc.
Modality	Small molecule
Phase	Phase 1

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

DNL919 CI brief — competitive landscape report
DNL919 updates RSS · CI watch RSS
Denali Therapeutics Inc. portfolio CI